General Information of Drug (ID: DMQSC5O)

Drug Name
Varlilumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 2 [1]
Head and neck cancer 2D42 Phase 2 [1]
Ovarian cancer 2C73 Phase 2 [1]
Recurrent glioblastoma 2A00.00 Phase 2 [2]
Renal cell carcinoma 2C90 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMQSC5O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CDX-527 DMVDIWO Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
CDX-1127 DMPVUGE leukaemia 2A60-2B33 Phase 1 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell activation antigen CD27 (CD27) TTDO1MV CD27_HUMAN Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
4 Clinical pipeline report, company report or official report of Celldex Therapeutics.